Agios Pharmaceuticals’ mitapivat meets primary endpoint in Phase 3 thalassemia trial

Agios Pharmaceuticals’ mitapivat meets primary endpoint in Phase 3 thalassemia trial

Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), renowned for its innovative therapies in cellular metabolism and pyruvate kinase (PK) activation, has announced promising results from its global Phase 3 ENERGIZE-T study. The study focused on mitapivat, a novel treatment for adults with transfusion-dependent alpha- or beta-thalassemia, achieving its primary endpoint of significant transfusion reduction, along with all […]